• Natera announced an enhanced Panorama non-invasive prenatal test using SNP-informed deep sequencing technology to improve performance in low fetal fraction samples.
• Results have already been generated in a prospective, blinded clinical validation study with outcomes confirmed by diagnostic genetic testing.
• The study indicated the updated test maintained strong detection capability in low fetal fraction cases, a setting that can raise the risk of missed abnormalities.
• Natera highlighted a lower no-call rate, positioning the update to reduce redraws and expand first-pass reportable results versus some counting-based NIPT approaches.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260525746777) on May 26, 2026, and is solely responsible for the information contained therein.